Euroapi: sharply widened net loss in 2023
The latter was penalized by less favorable absorption of fixed costs and inflation, while sales for the supplier of active pharmaceutical ingredients rose by 3.8% to 1.01 billion euros (+3.1% at constant exchange rates).
For 2024, Euroapi anticipates a core EBITDA margin of between 6 and 9%, as well as a decline in sales of between 4 and 7% on a comparable basis, due in particular to lower sales to Sanofi.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction